2020
Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing
Springer SA, Masciotra S, Johnson JA, Campbell S. Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing. Open Forum Infectious Diseases 2020, 7: ofaa478. PMID: 33204760, PMCID: PMC7651562, DOI: 10.1093/ofid/ofaa478.Peer-Reviewed Original Research
2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes
2017
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatment
2016
Co-calibration of two self-reported measures of adherence to antiretroviral therapy
Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2016, 29: 464-468. PMID: 27910703, PMCID: PMC5291764, DOI: 10.1080/09540121.2016.1263721.Peer-Reviewed Original ResearchConceptsVisual analog scaleAntiretroviral therapyAdherence measuresAIDS Clinical Trials Group questionnaireHigh-risk vulnerable populationsVulnerable populationsCare cohortAnalog scaleVAS scaleHIV StudyAdherence dataClinical successConsortium studyGroup questionnaireTherapyDosesSelf-report measuresAdherence
2015
Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective
Springer SA, Larney S, Alam-mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: s155-s161. PMID: 25978482, PMCID: PMC4443704, DOI: 10.1097/qai.0000000000000637.Peer-Reviewed Original ResearchConceptsMedication-assisted therapyDrug treatmentAntiretroviral therapyHIV transmission riskNew HIV infectionsHarm reduction servicesSubstance use disordersPoor treatment accessImplementation of interventionsOpioid useHIV infectionEvidence-based practiceHIV preventionOpioid addictionTreatment accessUse disordersReduction servicesSexual riskTransmission riskTherapyWomenTreatmentDrugsImpressive lackSignificant reduction
2012
Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroupThe Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic Review
Springer SA, Dushaj A, Azar MM. The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic Review. AIDS And Behavior 2012, 16: 2119-2143. PMID: 22644066, PMCID: PMC3481055, DOI: 10.1007/s10461-012-0212-3.BooksConceptsDSM-IV mental disordersCART adherenceAntidepressant treatmentHIV/AIDSMental disordersSystematic reviewCombination antiretroviral therapy (cART) adherenceCombination antiretroviral therapyAntiretroviral therapy adherenceMore anxiety disordersAntiretroviral therapyTherapy adherenceAnxiety disordersPersonality disorderAdherenceDisordersAdult personsAIDSDepressionMore researchAssociationRCTsReviewDepression measurementsTherapy
2011
Adherence to HIV Treatment and Care Among Previously Homeless Jail Detainees
Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL. Adherence to HIV Treatment and Care Among Previously Homeless Jail Detainees. AIDS And Behavior 2011, 17: 2654-2666. PMID: 22065234, PMCID: PMC3325326, DOI: 10.1007/s10461-011-0080-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceAnti-HIV AgentsCross-Sectional StudiesFemaleHealth Services AccessibilityHealth Services Needs and DemandHealthcare DisparitiesHIV InfectionsHumansIll-Housed PersonsInsurance CoverageInsurance, HealthMaleMedication AdherenceMental DisordersNeeds AssessmentPrisonersSubstance Abuse, IntravenousUnited StatesVulnerable Populations
2010
A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug And Alcohol Dependence 2010, 112: 178-193. PMID: 20705402, PMCID: PMC2997193, DOI: 10.1016/j.drugalcdep.2010.06.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care utilizationHIV treatment outcomesAlcohol use disorderPoor HIV treatment outcomesCare utilizationTreatment outcomesAntiretroviral therapyUse disordersImpact of AUDHealth service utilizationHIV/AIDSCD4 countHIV statusMedication adherenceService utilizationDATA SYNTHESISAnimal studiesElectronic databasesSystematic reviewAlcohol useTherapyPrimary articlesGoogle ScholarAdherenceOutcomesImproved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySubstance abuse treatment outcomesTreatment outcomesNon-detectable viral loadOpioid treatment outcomesBuprenorphine/naloxoneDSM-IV criteriaAgonist therapyAntiretroviral therapyCD4 countOpioid cravingAdverse eventsBuprenorphine treatmentOpioid dependenceViral loadUrine testingHIVTherapyVulnerable populationsWeeksOutcomesNLXTrialsInductionLikert scaleCommentary on Larney (2010): A call to action—opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid‐dependent prisoners
Springer SA. Commentary on Larney (2010): A call to action—opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid‐dependent prisoners. Addiction 2010, 105: 224-225. PMID: 20078481, PMCID: PMC2825564, DOI: 10.1111/j.1360-0443.2009.02893.x.Peer-Reviewed Original Research
2009
Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2008
A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.
Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. Journal Of Opioid Management 2008, 4: 81-6. PMID: 18557164, PMCID: PMC2476214, DOI: 10.5055/jom.2008.0012.Peer-Reviewed Original ResearchConceptsOpioid substitution therapySubstitution therapyAntiretroviral medicationsHIV riskDrug useOpioid-dependent prisonersConnecticut DepartmentPatient care capacityMaintenance therapyOpioid dependencyBUP treatmentTherapyReferral programBuprenorphineLess adherenceHIVMethadoneMinority of respondentsMajority of inmatesPilot studyAnonymous surveyMedicationsMore educationResults of answersAdherence
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisitsAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2004
Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount